| Name | Poolbeg Pharma |
|---|---|
| Epic | POLB |
| Isin | GB00BKPG7Z60 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 3.85p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £26.84 | Debt ratio | n/a |
| Shares in issue | 697.20 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | 2.03 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -1.16 | 52-week high / low | 2.40p / 9.10p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Poolbeg Pharma |
|---|---|
| Address | 40 Bank Street, Floor 24, London, United Kingdom, E14 5NR |
| Telephone | +44 (0)20 7183 1499 |
| Website | http://www.poolbegpharma.com/ |
| Director | Position |
|---|---|
| Mr Jeremy Skillington | CEO |
| Mr Ian O'Connel | CFO |
| Mr Cathal Friel | Executive Chairman |
| Mr Brendan Buckley | Independent Non-Executive Director |
| Mr Edward Gibson | Independent Non-Executive Director |
| Mr Luke O'Neill | Independent Non-Executive Director |
| Assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 31/12/24 | 31/12/23 | 31/12/22 |
| Intangible asssets and goodwill | 1.68 | 1.93 | 2.13 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 1.68 | 1.93 | 2.13 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | n/a | n/a | 0.96 |
| Cash and equivalents | 0.74 | 1.33 | 16.19 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 10.25 | 15.43 | 19.29 |
| Liabilities £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 0.97 | 0.99 | 0.97 |
| Long term liabilities | n/a | n/a | n/a |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 0.97 | 0.99 | 0.97 |
| Net assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | 9.27 | 14.44 | 18.32 |
| Equity £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 0.1 | 0.1 | 0.1 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -16.74 | -10.95 | -7.02 |
| Share premium account | 23.1 | 23.1 | 23.1 |
| Total equity | 9.27 | 14.44 | 18.32 |
| Income £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -6.37 | -5.04 | -4.99 |
| Pre-tax profit | -5.79 | -3.93 | -4.78 |